Evidence map›Paper›PMID 39269500›Full record

ArticlePsychopharmacology2024

Effect of chronic delivery of the NOP/MOR partial agonist AT-201 and NOP antagonist J-113397 on heroin relapse in a rat model of opioid maintenance.

Jennifer M Bossert, Kiera E Caldwell, Hannah Korah, Ashley Batista, Hannah Bonbrest, Ida Fredriksson, Shelley N Jackson, Agnieszka Sulima, Kenner C Rice, Nurulain T Zaveri and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Parabrachial CGRP Neurons Regulate Opioid Reinforcement.bioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jennifer M BossertBehavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, U.S.A.. jennifer.bossert@nih.gov.
Kiera E CaldwellBehavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, U.S.A.
Hannah KorahBehavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, U.S.A.
Ashley BatistaBehavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, U.S.A.
Hannah BonbrestBehavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, U.S.A.
Ida FredrikssonBehavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, U.S.A.
Shelley N JacksonTranslational Analytical Core, IRP/NIDA/NIH, Baltimore, MD, U.S.A.
Agnieszka SulimaMolecular Targets and Medications Discovery Branch, IRP/NIDA, NIAAA/NIH, Baltimore, MD, U.S.A.
Kenner C RiceMolecular Targets and Medications Discovery Branch, IRP/NIDA, NIAAA/NIH, Baltimore, MD, U.S.A.
Nurulain T ZaveriAstraea Therapeutics, 320 Logue Avenue, Mountain View, CA, USA.
Yavin ShahamBehavioral Neuroscience Branch, IRP/NIDA/NIH, Baltimore, MD, U.S.A.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleThe opioid crisis persists despite availability of effective opioid agonist maintenance treatments (methadone and buprenorphine). Thus, there is a need to advance novel medications for the treatment of opioid use and relapse.

objectivesWe recently modeled maintenance treatment in rats and found that chronic delivery of buprenorphine and the mu opioid receptor (MOR) partial agonist TRV130 decreases relapse to oxycodone seeking and taking. In contrast, chronic delivery of the buprenorphine analog BU08028 had mixed effects on different heroin relapse-related measures. Here, we tested the effect of the mixed nociceptin (NOP) receptor/MOR partial agonist AT-201 and the NOP receptor antagonist J-113397 on different heroin relapse-related measures.

methodsWe trained male and female rats to self-administer heroin (6-h/d, 14-d) in context A and then implanted osmotic minipumps containing AT-201 (0, 3.8, or 12 mg/kg/d) or J-113397 (0, 12.6, or 40 mg/kg/d). Next, we tested the effect of chronic delivery of the compounds on (1) incubation of heroin seeking in a non-drug context B, (2) extinction responding reinforced by heroin-associated discrete cues in context B, (3) context A-induced reinstatement of heroin seeking, and (4) reacquisition of heroin self-administration in context A.

resultsIn females, AT-201 modestly increased reacquisition of heroin self-administration and J-113397 modestly decreased incubation of heroin seeking. The compounds had no effect on the other relapse-related measures in females, and no effect on any of the measures in males.

conclusionThe NOP/MOR partial agonist AT-201 and the NOP antagonist J-113397 did not mimic buprenorphine's inhibitory effects on relapse in a rat model of opioid maintenance treatment.

Indexed as

HeroinNociceptin ReceptorReceptors, OpioidReceptors, Opioid, muRecurrenceSelf AdministrationAnalgesics, OpioidAnimalsBenzimidazolesDisease Models, AnimalDose-Response Relationship, DrugDrug-Seeking BehaviorExtinction, PsychologicalFemaleHeroin DependenceMaleAnalgesics, OpioidBenzimidazolesHeroinJ 113397Narcotic AntagonistsNociceptin ReceptorOprl1 protein, ratPiperidinesPyrimidinesReceptors, OpioidReceptors, Opioid, muContext-induced reinstatementExtinctionHeroin self-administrationIncubation of cravingOpioid maintenanceReacquisition

Identifiers

PMID39269500
PMCPMC11569015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.